Cyclerion Therapeutics, Inc.
CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, anā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.49
Price+1.45%
$0.05
1Y
Price
Market Cap
$15.113m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$1.993m
-3.9%
1y CAGR-0.1%
3y CAGR-25.0%
5y CAGREarnings
-$5.276m
-49.5%
1y CAGR-7.7%
3y CAGR+16.3%
5y CAGREPS
-$1.42
-30.3%
1y CAGR+22.1%
3y CAGR+30.4%
5y CAGRBook Value
$6.791m
$8.505m
Assets$1.714m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$3.588m
-8.3%
1y CAGR+31.6%
3y CAGR+35.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company